These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 33236471)

  • 1. Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. A real-life experience.
    Bonifati C; Morrone A; Cristaudo A; Graceffa D
    Dermatol Ther; 2021 Jan; 34(1):e14584. PubMed ID: 33236471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
    Torres T; Puig L; Vender R; Yeung J; Carrascosa JM; Piaserico S; Gisondi P; Lynde C; Ferreira P; Bastos PM; Dauden E; Leite L; Valerio J; Del Alcázar-Viladomiu E; Rull EV; Llamas-Velasco M; Pirro F; Messina F; Bruni M; Licata G; Ricceri F; Nidegger A; Hugo J; Mufti A; Daponte AI; Teixeira L; Balato A; Romanelli M; Prignano F; Gkalpakiotis S; Conrad C; Lazaridou E; Rompoti N; Papoutsaki M; Nogueira M; Chiricozzi A
    Am J Clin Dermatol; 2022 Nov; 23(6):891-904. PubMed ID: 35976568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment.
    Mastorino L; Dapavo P; Susca S; Cariti C; Siliquini N; Verrone A; Stroppiana E; Ortoncelli M; Quaglino P; Ribero S
    J Dtsch Dermatol Ges; 2024 Jan; 22(1):34-42. PubMed ID: 37926830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
    Torres T; Puig L; Vender R; Lynde C; Piaserico S; Carrascosa JM; Gisondi P; Daudén E; Conrad C; Mendes-Bastos P; Ferreira P; Leite L; Lu JD; Valerio J; Bruni M; Messina F; Nidegger A; Llamas-Velasco M; Del Alcazar E; Mufti A; White K; Caldarola G; Teixeira L; Romanelli P; Desai K; Gkalpakiotis S; Romanelli M; Yeung J; Nogueira M; Chiricozzi A
    Am J Clin Dermatol; 2021 Jul; 22(4):567-579. PubMed ID: 33786754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
    Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
    J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
    Dong J; Goldenberg G
    Cutis; 2017 Feb; 99(2):123-127. PubMed ID: 28319618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
    J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis).
    Gargiulo L; Ibba L; Malagoli P; Balato A; Bardazzi F; Burlando M; Carrera CG; Damiani G; Dapavo P; Dini V; Gaiani FM; Girolomoni G; Guarneri C; Lasagni C; Loconsole F; Marzano AV; Megna M; Mercuri SR; Travaglini M; Costanzo A; Narcisi A
    Front Immunol; 2023; 14():1341708. PubMed ID: 38274801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort.
    Viola R; Mastorino L; Megna M; Damiani G; Gisondi P; Argenziano G; Peris K; Prignano F; Burlando M; Conti A; Loconsole F; Malagoli P; Zalaudek I; Cacciapuoti S; Bellinato F; Balato A; De Simone C; Chersi K; Ortoncelli M; Quaglino P; Dapavo P; Ribero S
    Int J Dermatol; 2024 Mar; 63(3):351-358. PubMed ID: 38178802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Biologic Agents Targeting Interleukin-23 and Interleukin-17 for Moderate-to-Severe Psoriasis.
    Chen Z; Gong Y; Shi Y
    Clin Drug Investig; 2017 Oct; 37(10):891-899. PubMed ID: 28755058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
    Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
    J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study.
    Narcisi A; Valenti M; Cortese A; Toso F; Pavia G; Gargiulo L; Borroni R; Costanzo A
    Dermatol Ther; 2022 Feb; 35(2):e15228. PubMed ID: 34820969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis.
    Egeberg A; Andersen YMF; Halling-Overgaard AS; Alignahi F; Thyssen JP; Burge R; Mallbris L
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):39-46. PubMed ID: 31465593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics.
    Prignano F; Pescitelli L; Trovato E; DI Cesare A; Cuccia A; Mazzatenta C; Pellegrino M; Marsili F; Castelli A; Brandini L; Niccoli MC; Taviti F; Ricceri F; Panduri S; Buggiani G; Ghilardi A; Rubegni P; Romanelli M; Pimpinelli N
    Ital J Dermatol Venerol; 2022 Dec; 157(6):469-479. PubMed ID: 35785927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
    Tausend W; Downing C; Tyring S
    J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. English version of Japanese guidance for use of biologics for psoriasis (the 2022 version).
    Saeki H; Mabuchi T; Asahina A; Abe M; Igarashi A; Imafuku S; Okubo Y; Komine M; Sano S; Torii H; Morita A; Yotsuyanagi H; Watanabe A; Ohtsuki M;
    J Dermatol; 2023 Feb; 50(2):e41-e68. PubMed ID: 36582113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of emerging immunotherapies in psoriasis.
    Yiu ZZ; Warren RB
    Immunotherapy; 2015; 7(2):119-33. PubMed ID: 25713988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
    Yang K; Oak ASW; Elewski BE
    Am J Clin Dermatol; 2021 Mar; 22(2):173-192. PubMed ID: 33301128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA).
    Graier T; Weger W; Jonak C; Sator P; Zikeli C; Prillinger K; Sassmann C; Gruber B; Saxinger W; Ratzinger G; Painsi C; Mlynek A; Häring N; Sadoghi B; Trattner H; Müllegger R; Quehenberger F; Salmhofer W; Wolf P
    Sci Rep; 2022 Sep; 12(1):15078. PubMed ID: 36064563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-the BeNeBio study.
    van der Schoot LS; van den Reek JMPA; Grine L; Schots L; Kievit W; Lambert JLW; de Jong EMGJ
    Trials; 2021 Oct; 22(1):707. PubMed ID: 34656148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.